Abstract Library

#3062 The Splicing Factor CELF4 Is Dysregulated in Neuroendocrine Tumors, Where It Can Enhance Aggressiveness Features

Introduction: There is increasing evidence that alterations in alternative splicing are linked to key tumor features in different cancers. Besides mutations, dysregulation of the splicing machinery would represent the main underlying cause for these alterations. Indeed, splicing dysregulation is emerging as a novel, transversal cancer hallmark, due to its association with multiple dysfunctions in tumor cells.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Alors-Pérez E

Authors: Alors-Pérez E, Pedraza-Arévalo S, Vázquez-Borrego M, Blázquez-Encinas R, Herrera-Martínez A,

Keywords: PanNET, CELF4, splicing, aggressiveness, pituitary tumors,

#3030 Targeting CXCR4 and Thioredoxin Reductase in Theranostics of Atypical Carcinoid and Neuroendocrine Carcinoma

Introduction: Atypical carcinoid and small cell lung cancer (SCLC) are currently incurable. There is thus a critical need for new diagnostic and therapeutic strategies for lung neuroendocrine neoplasms (LNEN). Chemokine receptor 4 (CXCR4), a G protein coupled receptor and theranostic target, plays a crucial role in metastases of LNEN. We hypothesize combination of thioredoxin reductase (TR) inhibitor represents a metabolic strategy to enhance cytotoxicity in peptide-receptor radionuclide therapy (PRRT) of LNEN.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Liu D

Authors: Liu D, Fath M, Robles Planells C, Balk E, Bellizzi A,

Keywords: CXCR4, thioredoxin reductase inhibitor, theranostics, atypical carcinoid, small cell lung cancer,

#2980 Metabolic Dysregulation and Circadian Clock in Cellular Models of Neuroendocrine Tumors

Introduction: The circadian clock genes encode transcription factors whose interaction with nuclear receptors allows the regulation of cellular metabolism.The invalidation of the genes of the clock core is associated with the development of many endocrine diseases including neuroendocrine cancer. Recently, the family of transcriptional coactivators PGC-1a has been identified as a key element in the integration of cellular metabolic state with the circadian clock. PRC, as a member of the PGC-1 family, was able to interact with several transcription factors, including the CLOCK factor. The specific induction of this PRC factor by the cell cycle, to modulate the energy function, the MAPkinase pathway and the expression of microRNAs, makes it a key factor in the metabolic adaptation of cancer cells.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Savagner F

Authors: Savagner F, Le Pennec S,

Keywords: Metabolism, Circadian clock, cell models,

#2974 MEK/RAF and PARP as Novel Targets in Neuroendocrine Neoplasms – First Results from a Molecular in vitro Tumor Board

Introduction: Neuroendocrine neoplasms (NEN) are a heterogeneous group comprising well differentiated neuroendocrine tumors (NET) and poorly differentiated neuroendocrine carcinomas (NEC). Although, major progress has been made in the development of targeted therapies in various cancers, establishment of a promising personalized therapy in NEN is still pending. So far, a lack of suitable preclinical models represent a major challenge concerning the validation of a mutational based targeted therapy (MBTT)

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Viol F, Sipos B, Amin T, Fahl M, Grabowski P,

Keywords: Neuroendocrine neoplasms, Personalized therapy, Preclinical in vitro models, Mutational based targeted therapy,

#2910 Virotherapy Shows Promising Efficacy in Neuroendocrine Cancers

Introduction: So far, there have been only two clinical studies using virotherapeutics to treat neuroendocrine cancers (NCT00314925 & NCT02749331). Notably, none of these approaches employed a clinically approved virotherapeutic compound.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Lauer U

Authors: Lauer U, Berchtold S, Smirnow I, Schaller M, Fehrenbacher B,

Keywords: neuroendocrine, cancer, virotherapy, virotherapeutics, preclinical, research,